
First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers
First-line treatment of Keytruda (pembrolizumab) plus eftilagimod alfa (Efti) elicited an overall survival (OS) of 17.6 months in patients with recurrent/metastatic head and neck squamous cell carcinoma and a PD-L1 expression below one (combined …